NovaBridge Reports 79% Response Rate for Givastomig at Selected Dose in Phase 1b Trial

PUBT · 1d ago
NovaBridge Reports 79% Response Rate for Givastomig at Selected Dose in Phase 1b Trial
  • NovaBridge Biosciences presented updated Phase 1b results for givastomig at ESMO 2026, supporting advancement toward registrational development.
  • Givastomig combined with nivolumab and chemotherapy showed durable clinical benefit in patients with HER2-negative, first-line metastatic gastroesophageal adenocarcinoma.
  • Activity extended across CLDN18.2 expression levels, including lower-expression tumors ineligible for currently approved CLDN18.2-targeted therapies.
  • The selected 8 mg/kg dose showed a favorable benefit-risk profile, with no Grade 4 or Grade 5 treatment-related adverse events attributed to givastomig.
  • FDA alignment on a global Phase 3 study protocol supports registrational planning, alongside existing Orphan Drug and Fast Track designations.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-430974), on October 26, 2026, and is solely responsible for the information contained therein.